BNC 210
Alternative Names: BNC-210; IW 2143Latest Information Update: 30 Oct 2025
At a glance
- Originator Bionomics
- Developer Bionomics; EmpathBio
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Anxiety disorders
- Phase II Agitation; Post-traumatic stress disorders
- No development reported Depressive disorders
Most Recent Events
- 21 Oct 2025 Neuphoria Therapeutics plans to evaluate next steps for further development of BNC 210 in post-traumatic stress disorder
- 29 Sep 2025 Neuphoria Therapeutics plans to initiate the phase IIb/III SYMPHONY trial in Post-traumatic stress disorder (PO) in the first half of 2026
- 20 May 2025 Neuphoria Therapeutics completes an end of phase II meeting with the US FDA for a phase IIb (SYMPHONY) trials in Post traumatic stress disorders